Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. - Wikidata - awgldk - TriplyDB

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

http://www.wikidata.org/entity/Q33330997

about

Surgery for colorectal liver metastases: The evolution of determining prognosis Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy.Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience.Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.An update on chemotherapy of colorectal liver metastases Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer.Management of potentially resectable colorectal cancer liver metastases Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.What is the optimal neo-adjuvant treatment for liver metastasis?Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection.Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.Optimal timing of systemic therapy in resectable colorectal liver metastases.Accomplishments in 2008 in the management of curable metastatic colorectal cancer.Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.Metastatic colorectal cancer: recent advances in its clinical management.Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.Role of surgery in colorectal liver metastases: too early or too late?Advances in therapeutics for liver metastasis from colorectal cancer.The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases.Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review.Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.Multidisciplinary approach of colorectal liver metastases.Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.The developing clinical problem of chemotherapy-induced hepatic injury.Meeting the biologic challenge of colorectal metastases.Prognostic factors after resection of colorectal liver metastases: from morphology to biology.Liver resection with concomitant inferior vena cava resection: experiences without veno-venous bypass.Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer.Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case.Perioperative chemotherapy for resectable colorectal hepatic metastases-What does the EORTC 40983 trial update mean?Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.

P2860

Q27694490-49096A78-F6BF-43FA-AEFF-E6CE5312A98D Q33477125-44F65616-32CF-49E0-955B-0F8381657292 Q33865047-1D6B65A9-F528-4EC2-8AB2-C6D76BF14D1C Q34013522-87930C0E-7BEE-4C42-8116-0E078FF9E7F6 Q35210685-A197F6FC-04CC-4A27-90DE-961644A2D741 Q35653578-250C8BAE-8F9D-4397-A5C0-559EF82A52F7 Q35854745-C3B03CBD-0AE2-4B6C-8CFB-F92B5A44705B Q36286831-247914AB-3053-46AF-9549-EC4FACC0C4FE Q36871770-8A84392B-9E94-410A-9999-8A8696C20B71 Q36984725-FD1A6191-E5E0-4917-A638-4107C1BB3EE4 Q36999699-9111340B-976C-4046-BE5D-4CFE3902FCCE Q37049057-1158B4F5-2323-4F27-9AAF-B39B0E68DD08 Q37352557-1C599E40-EBD9-4FA4-8D48-609C6A099284 Q37358002-A47DE865-346A-4BA1-8513-CA8DD3E91028 Q37466299-D6672571-CC62-48F1-9CD6-A4B3E5FBD749 Q37468824-A899A596-85FE-42D7-A83E-5C00CE7B0725 Q37500453-F89A7B7F-55EA-42DA-9FBD-F9CCFC5BB092 Q37642801-583EF828-34E4-4850-B2E5-B7C0322DF3D7 Q37708019-A02A5823-E856-4699-8C3F-BF09252CBDF4 Q37774980-B0447F33-163B-4E73-8679-B8FA37C8391B Q37821285-833E53BE-1A2E-4A9B-B970-156C024A0DB3 Q37821836-7B88425B-BB8D-4B08-8A92-E912A6331A9A Q37821845-298B2082-9D32-4EAA-AE53-0B9214AF8294 Q37904901-ADA87F29-807F-4E95-85EF-CC49FBAEC40D Q37907117-B49361B1-2DB8-4DFD-A93D-E3787CADD424 Q37942736-A8EC0A91-D33A-4C7E-BFB2-0863647F7DDB Q37951604-0EEF0474-203D-4154-9AF2-67327C7EE09A Q38002990-0AB80F1D-3A11-4632-955B-ED97F4035274 Q38051068-AE83954A-927D-45CF-B504-7463036C5547 Q38068492-74B26880-BD39-4570-9C98-BE1E629FC1EF Q38117053-C4CFC6CF-AE7B-4EA8-92A3-E5A2B05DC183 Q38493122-40CDD185-341F-47E2-A20D-852D18AC3B49 Q38938329-9EE950F2-EC6B-4EA5-A0E5-50C386F8D0E1 Q39111898-2996B553-EF20-456C-B688-0B73A85FAFB2 Q40073318-A5BD8A52-BF82-4C69-B233-A4DC41C216D1 Q41234320-2B78286B-74CF-4B1C-AE47-78A1B1613695 Q43134848-BD2314F8-B737-43D3-9C6B-0038616DFA52 Q43413801-E54E3C75-F4D5-4109-A0F3-3F9AB9F44166 Q52962069-F5EE3E8A-D4B7-47FB-8390-2D94D97DC553 Q54480507-6EBC1736-5D2E-4ED1-B8DD-DACE26890E57

P2860

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

http://www.wikidata.org/entity/Q33330997

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Importance of response to neoa ...... ectal cancer liver metastases.

@ast

Importance of response to neoa ...... ectal cancer liver metastases.

@en

Importance of response to neoa ...... ectal cancer liver metastases.

@nl

type

label

Importance of response to neoa ...... ectal cancer liver metastases.

@ast

Importance of response to neoa ...... ectal cancer liver metastases.

@en

Importance of response to neoa ...... ectal cancer liver metastases.

@nl

prefLabel

Importance of response to neoa ...... ectal cancer liver metastases.

@ast

Importance of response to neoa ...... ectal cancer liver metastases.

@en

Importance of response to neoa ...... ectal cancer liver metastases.

@nl

P1433

Q33330997-1B6A1403-2FE4-4B67-BFCC-8F4EE0AC3696

P1476

Q33330997-84A7C889-06D7-4135-9C86-28803E8B9A36

P2093

Q33330997-478688C1-B079-4104-BC9E-4DD15F465274

Q33330997-5C59F77F-5E0A-42D0-A84A-C9A3384A3491

Q33330997-65388A14-0B9C-4E1A-82D0-DBB6A8CF1FCC

Q33330997-872BF6A8-DA23-459F-8FF5-77B4253CB0FE

Q33330997-F9C0D778-1475-4393-8447-AC1338C7848E

P2860

Q33330997-119E83A6-7AF6-4903-B052-056E57C492D5

Q33330997-12B2C879-C38C-4AD0-BD89-2595DCFAD853

Q33330997-346E9C5D-0728-4F8D-8FB7-0959861A979F

Q33330997-35C6BA52-6D2E-49A5-9F69-0B992F542CE0

Q33330997-395AD689-5064-4952-A073-30F7705479B1

Q33330997-3BEE4582-2B57-413F-BEBE-21892C4CE47D

Q33330997-3C19BF21-0A85-4099-8B1E-E7FF007C6426

Q33330997-4E347B57-43D5-493F-8349-2D824B7B9EF4

Q33330997-6E5E4D03-D6F6-4759-AF96-54D0FEEAAD42

Q33330997-77045C9B-6867-4CB8-800B-E14A6C1E29B4

P2888

Q33330997-3D28A14D-E6D9-4D2D-BA9D-7120B4A20BF5

P304

Q33330997-550C8E4F-D74D-4E5A-9546-423CDC644EF1

P31

Q33330997-EA7C27A7-D0BA-47E8-915B-3DE50647DEBE

P356

Q33330997-85A973F6-E4FC-4273-A53A-CC30BF189772

P407

Q33330997-EDAF0D07-03EE-4667-B41F-882D66FF5630

P478

Q33330997-1EBC4B18-E99B-4835-8DAF-B66C033B280B

P50

Q33330997-8C4DEF6D-C7FF-47B5-9BEE-0A96C853AC6B

P577

Q33330997-E1F54545-4832-4D3C-9033-E55EA4E6047E

P5875

Q33330997-B22D1B80-E19E-451D-87CE-D55E9F68B2F9

P6179

Q33330997-F5AD810C-7083-4E1C-85DB-412FF02E60F1

P698

Q33330997-2253E250-9340-4F69-8E2B-AF291DC025EA

P921

Q33330997-27AF61C7-940C-4C1F-BFDC-56D4A229E861

Q33330997-E8E3842C-D0F2-4215-B242-524377F7AB98

P932

Q33330997-071E39DA-C146-41A1-B03F-7555AB219312

P356

1471-2407-8-120

P1433

P1476

Importance of response to neoa ...... rectal cancer liver metastases

@en

P2093

Birgit Gruenberger

http://www.w3.org/2001/XMLSchema#string

Christoph Zielinski

http://www.w3.org/2001/XMLSchema#string

Robert Punzengruber

http://www.w3.org/2001/XMLSchema#string

Thomas Gruenberger

http://www.w3.org/2001/XMLSchema#string

Werner Scheithauer

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.

P2888

1471-2407-8-120

P304

120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-8-120

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Dietmar Tamandl

P577

2008-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5414188

http://www.w3.org/2001/XMLSchema#string

P6179

1037616467

http://www.w3.org/2001/XMLSchema#string

P698

18439246

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2386791

http://www.w3.org/2001/XMLSchema#string